MPS IX (Natowicz Syndrome)

Also known as: Mucopolysaccharidosis IX, Natowicz syndrome, Hyaluronidase deficiency

What is it?

MPS IX is caused by a mutation (change) in the HYAL1 gene. This leads to a deficiency in an enzyme called hyaluronidase which is needed to breakdown mucopolysaccharide hyaluronan. When hyaluronan is not broken down entirely, it stays stored in the body. This build-up of hyaluronan in the tissues in the body causes the symptoms associated with the condition. Babies usually show little sign of the condition, but as more and more cells build up, symptoms start to appear.

How common is it?

MPS IX is an extremely rare condition that was first noted in 1996. Only one case of MPS IX has been reported to date.

Signs & Symptoms

Symptoms of MPS IX may include: • Mild short stature • Cysts • Frequent ear infections • Cleft palate • Flattened nose bridge • Development of soft-tissue masses *However, more cases of MPS IX must be identified before a clear clinical picture of symptoms can be established.

Causes & Inheritance

Mutation in the HYAL1 gene.

MPS IX is an inherited condition. Humans have chromosomes made up of DNA. Genes are pieces of DNA that carry the genetic information. Each chromosome may have several thousand genes. We inherit chromosomes from the egg of the mother and sperm of the father. The genes on those chromosomes carry the instructions that determine a person’s characteristics, which are a combination of the parents. The pattern of inheritance of MPS IX is autosomal recessive. This means that carriers of the condition do not have the disorder because the other gene of this pair is working normally. Parents of children with MPS IX are carriers. When both parents are carriers, the risk to the baby in each pregnancy is • 25% chance (1 in 4) of developing the condition • 50% chance (1 in 2) for the baby to be a carrier of the condition • 25% chance (1 in 4) for the baby to have two working genes and neither have the condition nor be a carrier Genetic counselling can be requested to get a full explanation.

Diagnosis

Enzyme assays (testing a range of cells or blood in culture for enzyme deficiency) are used to provide a diagnosis. Individuals with the condition will show a deficiency in the enzyme hyaluronidase.

Treatment

The treatment for this condition is symptomatic and supportive as there has been no effective drug treatment so far. The aim of this treatment is to manage and alleviate individual symptoms and provide support for the patients and their families.

Disclaimer: The information provided here is for educational purposes only and should not be taken as medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment. Information sourced from reliable medical databases.

Beyond MPS IX (Natowicz Syndrome): The Rare Disease Landscape

While MPS IX (Natowicz Syndrome) has its unique clinical manifestations and genetic triggers, most Lysosomal Storage Disorders (LSDs) share a common biological mechanism: the accumulation of cellular waste due to enzyme deficiency.

In the Indian context, the diagnostic odyssey for rare genetic conditions often spans several years, involving multiple medical specialists before a definitive diagnosis is reached. Taraasha Foundation is committed to simplifying this journey through education and specialized support.

We advocate for early clinical intervention and universal newborn screening to detect these conditions before the onset of irreversible symptoms. Understanding the inheritance patterns and the biological basis of metabolic shifts is a vital step for affected families.

Through Enzyme Replacement Therapy (ERT) and emerging gene therapies, the goal of modern medicine remains the same: ensuring a sustainable quality of life and empowering patients to lead fulfilling lives despite their diagnosis.